Repatha's Heart Benefits Are Driving Labelling Changes

September 2018

The "PCSK9 inhibitor" Repatha (evolocumab) labelling has changed...now that it has a new indication.

Repatha used to only be approved for lowering cholesterol in patients with certain genetic conditions.

But now it's approved for patients with cardiovascular (CV) disease to reduce their chance of having a heart attack or stroke.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Vaccines Stay Sharp to Prevent Errors With Vaccines
Recalls Navigate Through the Valsartan Recall
Lice Sort Through Head Lice Treatments
Cannabinoids Be Ready for Questions About Cannabidiol (CBD)
Eczema Know How Eucrisa and Dupixent Stack Up Against Other Eczema Meds
Diabetes & Endocrinology Keep Meds for Male-Pattern Hair Growth in Women Straight
Antibiotics Expect Less Use of Quinolones Based on the Latest Warnings
Psoriasis Think of Siliq as Similar to Cosentyx or Taltz for Plaque Psoriasis
Cardiology Repatha's Heart Benefits Are Driving Labelling Changes
Gout Watch for Some Gout Patients to Switch From Uloric to Allopurinol